UK regulator backs Amarin’s cardiology drug VazkepaAmarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the Share XUK regulator backs Amarin’s cardiology drug Vazkepahttps://pharmaphorum.com/news/uk-drugs-regulator-backs-amarins-cardiology-drug-vazkepa/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
RHYTHM AI cleared for large trial of atrial fibrillation mapping toolUK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, Share XRHYTHM AI cleared for large trial of atrial fibrillation mapping toolhttps://pharmaphorum.com/news/rhythm-ai-cleared-for-large-trial-of-atrial-fibrillation-mapping-tool/
Regeneron’s cholesterol drug evinacumab claims February FDA dateThe FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that Share XRegeneron’s cholesterol drug evinacumab claims February FDA datehttps://pharmaphorum.com/news/regenerons-cholesterol-drug-evinacumab-claims-february-fda-date/
AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
FDA approves Caption Health’s AI-driven cardiac ultrasound softwareThe FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without Share XFDA approves Caption Health’s AI-driven cardiac ultrasound softwarehttps://pharmaphorum.com/news/fda-approves-caption-healths-ai-driven-cardiac-imaging-software/
